D
The startup develops a non-injectable somatostatin analog that provides an alternative to traditional injectable growth hormone inhibitors used in the treatment of acromegaly and neuroendocrine tumors. This therapeutic approach offers patients a non-invasive option for short-acting therapy, enhancing treatment accessibility and comfort.
San Diego, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a non-injectable somatostatin analog that provides an alternative to traditional injectable growth hormone inhibitors used in the treatment of acromegaly and neuroendocrine tumors. This therapeutic approach offers patients a non-invasive option for short-acting therapy, enhancing treatment accessibility and comfort.